PGParbeer Grewal

Parbeer Grewal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Parbeer Grewal has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Implications of Interleukin-17 as a Hepato-Dermal Link in Patients With Psoriasis and Concomitant Steatotic Liver Disease

    by Elaine C. Dupuis, Patrick Fleming, Rami Abou Zeinab, Bridgette Hartley, Maxime Barakat, Parbeer Grewal

    Psoriasis is increasingly recognized as a systemic inflammatory disease with impacts beyond the skin and joints. Metabolic dysfunction-associated steatotic liver disease (MASLD) and excessive alcohol consumption are common in the psoriasis population, affecting up to two-thirds of patients. Interleukin-17 (IL-17) has been identified as a potential key pro-inflammatory link between psoriasis and MASLD. IL-17 levels have been positively correlated with progression of MASLD to more advanced forms of liver disease, including steatohepatitis, cirrhosis and hepatocellular carcinoma. Given the high prevalence of concurrent psoriasis and liver disease, dermatologists should have an elevated index of suspicion of MASLD in patients with psoriasis, particularly those with concomitant metabolic risk factors and/or excessive alcohol consumption. Using 3 parameters, the Fibrosis-4 index is a validated, non-invasive screening tool that can be implemented in clinical practice. With the wide variety of therapeutics available to treat psoriasis, practitioners should be mindful of systemic agents carrying potential hepatotoxic adverse effects and could consider instead implementation of advanced therapies that have neutral or potentially beneficial effects on the liver. There is emerging data, pending larger prospective confirmatory studies, that support consideration of IL-17 inhibitors as a reasonable option in appropriate patients with or at risk of MASLD.

  • Open Access

    Real-World Evidence of Upadacitinib in Atopic Dermatitis after Inadequate Response or Intolerance to Dupilumab: The CAN UpTIMISE Study

    by Vimal H. Prajapati, Vipul Jain, Melinda J. Gooderham, Michael Cecchini, Jason K. Lee, Charles W. Lynde, Parbeer Grewal, Andrew Ferrier, David Préfontaine, Carly Sterling, et al.

  • Open Access

    Canadian Treat-to-Target Practice Survey of Real-World Interventions and Strategies in Psoriasis (CAN TARGET PSORIASIS)

    by Jensen Yeung, Parbeer Grewal, Perla Lansang, Ron Vender, Marni Wiseman, Rami Abou Zeinab, Maxime Barakat, Vimal H. Prajapati

    Treat-to-target (T2T) strategies have been proposed to support decision-making in chronic plaque psoriasis care, but their use in Canadian clinical practice has not been well studied. This retrospective chart review examined how Canadian T2T criteria are applied for adult patients with moderate-to-severe plaque psoriasis and whether treatment decisions reflect treatment target achievement in clinical practice. Charts from 438 adults who initiated or modified biologic therapy and completed two visits 3-8 months apart were included. Treatment target achievement at visit 2 was assessed using predefined major and minor criteria, which included Psoriasis Area and Severity Index (PASI), body surface area (BSA), Physician Global Assessment (PGA), and Dermatology Life Quality Index (DLQI) outcome measures. Of the 438 patients, 321 (73.3%) met the treatment target and 98.4% of these continued their current biologic therapy. Among the 117 patients who did not meet the treatment target, 48.7% of remained on their current biologic therapy. Treatment target achievement was associated with lower PASI, BSA, PGA, and DLQI scores. DLQI influenced treatment modification even when treatment targets were unmet. Switching between interleukin (IL)-17 and IL-23 inhibitors was the most frequent treatment modification strategy. Findings support the clinical value of Canadian T2T criteria, while highlighting the importance of shared decision-making. Many patients who did not meet treatment targets remained on their current biologic therapy, emphasizing the role of patient input, quality of life, and physician judgment. These results reinforce the importance of balancing treatment targets with individualized care in real-world plaque psoriasis management.

  • Open Access

    Management of Moderate‐to‐Severe Atopic Dermatitis With Systemic Medications: Review and Expert Commentary

    by David N. Adam, Gurbir Dhadwal, Parbeer Grewal, Julien Ringuet, Irina Turchin, Jennifer Beecker

    Background: The systemic treatment of moderate‐to‐severe atopic dermatitis (AD) in adults has evolved significantly over the past decade in terms of treatment goals and therapeutic options. While many therapeutic options are endorsed by existing guidelines, newer therapies have been held to higher standards of efficacy and safety in clinical trials compared to “traditional” immunosuppressants used in AD. The robust evidence demonstrating the improved benefit‐to‐risk profiles of these newer medications implies that they should be prioritized, as they are more likely to enable patients to achieve modern treatment goals with less risk of adverse events. Objectives: To develop an evidence‐based algorithm for the systemic treatment of moderate‐to‐severe AD in adults, with a focus on the Canadian context, and prioritizing strength of evidence and safety over other factors such as cost and reimbursement. Methods: An expert panel of 6 Canadian dermatologists with expertise in AD identified randomized clinical trials and publications from prospective registries reporting on ≥ 100 adults taking systemic treatment for AD. The evidence supporting the various therapeutic options was summarized, evaluated, and synthesized into a draft evidence‐based algorithm for the systemic treatment of moderate‐to‐severe AD. Results and Implications: The evidence summaries were reviewed and discussed to create a new therapeutic algorithm, which was then refined through iterative review by all authors. This algorithm can provide evidence‐based support for decision‐making in the systemic treatment of moderate‐to‐severe AD in Canada and beyond.

  • Open Access

    A Clinician’s Guide to Topical Retinoids

    by Melika Motamedi, Ahmad Chehade, Ravina Sanghera, Parbeer Grewal

    Retinoids are defined as molecules that bind to and activate retinoic acid receptors to influence the proliferation and differentiation of cells. Topical retinoids have evolved over the past several decades, being used in multiple dermatological conditions. This review aims to differentiate between synthetic and natural retinoids, discuss the pharmacology behind topical retinoids, highlight clinical applications, and categorize all the commercially available agents, including combination products. Understanding retinoid affinities for unique receptor subtypes can impact clinical decisions, resulting in optimizing treatment and enhancing patient adherence.


  • Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper

    by Jensen Yeung, Melinda J. Gooderham, Parbeer Grewal, Chih-Ho Hong, Perla Lansang, Kim A. Papp, Yves Poulin, Irina Turchin, Ronald Vender

    Background: Plaque psoriasis (PsO) is a chronic inflammatory disease that often presents at peak reproductive age in women of child-bearing potential (WOCBP). With the emergence of biologic therapies to treat PsO, guidance on disease management in WOCBP is needed to inform treatment decisions before, during, and after pregnancy. Objectives: To develop a practical, up-to-date consensus document, based on available evidence and expert opinion where evidence was lacking, in order to guide both Canadian and international clinicians treating PsO in WOCBP. Methods: A panel of 9 Canadian dermatologists with extensive clinical experience managing PsO reviewed the relevant literature from the past 25 years in 3 key domains: overview of PsO in WOCBP and clinical considerations, treatment considerations, and postpartum considerations. The structured literature search focused on WOCBP treated with TNF-alpha inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab), IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab), IL-12/23 inhibitors (ustekinumab), and IL-17 inhibitors (brodalumab, ixekizumab, secukinumab). This literature review, along with clinical expertise and opinion, was used to develop concise and clinically relevant consensus statements to guide practical management of PsO in WOCBP. Experts voted on the statements using a modified Delphi process and prespecified agreement cut-off of 75%. Results and implications: After review, discussion, and voting on 19 draft consensus statements at an in-person meeting and remotely, 12 consensus statements were approved by the expert panel. The statements presented here will guide healthcare providers in practical disease management using biologic therapies for the treatment of PsO in WOCBP.


  • Off-Label Therapeutic Potential of Crisaborole

    by Caitlyn Makins, Ravina Sanghera, Parbeer S. Grewal

    Crisaborole, a topical phosphodiesterase-4 inhibitor, was recently approved in 2016 for the treatment of mild to moderate atopic dermatitis in adults and children greater than 2 years of age. Since that time, several case reports and a small randomized controlled trial have been published regarding the off-label use of crisaborole for the treatment of other inflammatory dermatologic disorders. This paper reviews the current, albeit limited, evidence for off-label use of crisaborole for psoriasis, seborrheic dermatitis, vitiligo, and inflammatory linear verrucous epidermal nevus. Additional potential therapeutic uses for crisaborole are also postulated, based on its mechanism of action. Future studies are required to elucidate the full therapeutic potential of crisaborole; however, it is a welcome addition to the current nonsteroid topical treatments for inflammatory dermatologic disease.


  • Psoriasis and Psoriatic Arthritis

    by Parbeer S. Grewal, Walter P. Maksymowych, Alain Brassard

  • Inflammatory Bowel-Associated Spondyloarthropathy

    by Parbeer S. Grewal, Walter P. Maksymowych, Alain Brassard